Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan.
Department of Pathology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan.
J Clin Exp Hematop. 2020 Sep 25;60(3):78-86. doi: 10.3960/jslrt.20010. Epub 2020 Jul 8.
Classic Hodgkin lymphoma (CHL) is a lymphoid neoplasia characterized by the presence of large tumor cells, referred to as Hodgkin and Reed-Sternberg (HRS) cells, originating from B-cells in an inflammatory background. As the clinical significance of B-cell markers has yet to be fully elucidated, this study aimed to clarify the clinicopathological significance of CD79a in 55 patients with CHL. They were immunohistochemically divided into two groups, comprising of 20 CD79a-positive and 35 CD79a-negative patients. There was no significant correlation between CD79a and CD20 expression (r = 0.125, P = 0.362). CD79a-positive patients were significantly older at onset (P = 0.011). There was no significant correlation between CD79a-positivity and clinical stage (P = 0.203), mediastinal involvement (P = 0.399), extranodal involvement (P = 0.749), or laboratory findings, including serum levels of lactate dehydrogenase (P = 1) and soluble interleukin-2 receptor (P = 0.251). There were significant differences in overall survival (OS) (P = 0.005) and progression-free survival (PFS) (P = 0.007) between CD79a-positive and CD79a-negative patients (5-year OS: 64.6% and 90.5%; 5-year PFS: 44.0% and 76.6%, respectively). Five patients in whom the majority (> 80%) of HRS cells expressed CD79a consisted of 4 males and 1 female aged between 52 and 81 years; 4 of them were in a limited clinical stage. We concluded that CD79a-positive CHL may have unique clinicopathological features.
经典霍奇金淋巴瘤 (CHL) 是一种淋巴肿瘤，其特征是存在大肿瘤细胞，称为霍奇金和里德-斯特恩伯格 (HRS) 细胞，源自炎症背景下的 B 细胞。由于 B 细胞标志物的临床意义尚未完全阐明，本研究旨在阐明 55 例 CHL 患者中 CD79a 的临床病理意义。他们通过免疫组织化学方法分为两组，包括 20 例 CD79a 阳性和 35 例 CD79a 阴性患者。CD79a 与 CD20 表达之间无显著相关性 (r = 0.125, P = 0.362)。CD79a 阳性患者发病时年龄明显较大 (P = 0.011)。CD79a 阳性与临床分期 (P = 0.203)、纵隔受累 (P = 0.399)、结外受累 (P = 0.749) 或实验室发现，包括血清乳酸脱氢酶 (P = 1) 和可溶性白细胞介素-2 受体 (P = 0.251) 之间无显著相关性。CD79a 阳性和 CD79a 阴性患者的总生存期 (OS) (P = 0.005) 和无进展生存期 (PFS) (P = 0.007) 存在显著差异 (5 年 OS：64.6%和 90.5%；5 年 PFS：44.0%和 76.6%）。在大多数 (> 80%) HRS 细胞表达 CD79a 的 5 例患者中，包括 4 名男性和 1 名女性，年龄在 52 至 81 岁之间；其中 4 例处于局限性临床分期。我们得出结论，CD79a 阳性 CHL 可能具有独特的临床病理特征。
